Johnson & Johnson $JNJ Shares Sold by Moody Lynn & Lieberson LLC

Key Points

• Moody Lynn & Lieberson LLC reduced its stake in Johnson & Johnson by 23.1%, holding 102,410 shares after selling 30,766 shares in the second quarter.
• Executives also engaged in insider trading, with EVP Jennifer L. Taubert selling 56,471 shares for over $10 million, marking a 24.08% decrease in her ownership.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, reflecting an annualized dividend yield of 2.9% and a payout ratio of 55.61%.

Moody Lynn & Lieberson LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,410 shares of the company's stock after selling 30,766 shares during the period. Johnson & Johnson comprises approximately 0.9% of Moody Lynn & Lieberson LLC's portfolio, making the stock its 26th largest position. Moody Lynn & Lieberson LLC's holdings in Johnson & Johnson were worth $15,643,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Highline Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $181.63 on Tuesday. The company has a 50-day simple moving average of $174.76 and a 200-day simple moving average of $162.18. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.87. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market capitalization of $437.43 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 2.29 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the company earned $2.82 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Barclays boosted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $181.40.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.